Balyasny Asset Management
NEUP

Balyasny Asset Management’s Neuphoria Therapeutics NEUP Stock Holding History

Balyasny Asset Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$579K Buy
+142,183
New +$601K ﹤0.01% 2308

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Balyasny Asset Management's NEUP Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Neuphoria Therapeutics (NEUP) in Q1 2026: 142,183 shares worth $579K. The stake represents ﹤0.01% of the portfolio and ranks #2308 among its holdings.

19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Balyasny Asset Management held 142,183 shares of Neuphoria Therapeutics worth $579K as of Q1 2026.
  • Neuphoria Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2308 holding.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.